AMRX vs IONS · P/E 44, rev $1.52B vs rev $514.0M
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Ionis Pharmaceuticals Inc (IONS) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Ionis Pharmaceuticals Inc (IONS) is a biotechnology company listed on NASDAQ.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported IONS revenue for 2026-06-30 was $514.0M. Net income was -$207.2M. IONS currently screens at market cap $12.28B.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. IONS currently screens at market cap $12.28B.
Not investment advice. Open the AMRX and IONS stock pages for the full models.
Not investment advice.